Psoriasis is a lifelong, autoimmune inflammatory disease. It often appears as a skin condition, but it is a systemic condition that can affect many parts of the body.
Psoriasis often causes skin lesions, but also a higher risk of other conditions, such as celiac, inflammatory bowel disease, and mental health issues. Find out more.
This study builds on an earlier paper by the Rothstein lab that looked at the most common genetic cause of ALS, a mutation in the C9orf72 gene (also referred to as the “C9 mutation”). There, they showed that the C9 mutation produced defects in a structure called the nuclear pore that is responsible for moving proteins and other molecules in and out of the nucleus of cells.
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal degenerative disease affecting the nerve cells in the brain and spinal cord responsible for controlling voluntary muscle movement. “Sporadic” or non-inherited ALS, accounts for roughly 90% percent of cases, and 10% of cases are due to known genetic mutations. By studying lab-grown neurons derived from skin or blood cells from 10 normal controls, eight with an ALS causing mutation, and 17 with non-inherited ALS, researchers have found a possible starting point for the dysfunction that causes the disease. The study, which was published in Science Translational Medicine, was funded in part by the National Institute for Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
Using a library of ALS patient-derived cells, the research team led by Jeffrey Rothstein, M.D., Ph.D., at Johns Hopkins University School of Medicine, Baltimore, developed induced pluripotent stem cell (iPSC)-derived neurons from the patients’ cultured cells to discover a common defect regardless of whether the cell came from persons with inherited or non-inherited ALS. They report that in ALS nerve cells, there is an accumulation of a protein called CHMP7 in the nucleus of cultured nerve cells as well as in ALS samples from the brain region that controls movement. Treatments that decrease the amount of CHMP7 in the cultured cells prevented a series of abnormalities that are characteristic of ALS.
“There is considerable interest in identifying new therapeutic targets for ALS, particularly for the sporadic form of the disorder,” said Amelie Gubitz, Ph.D., program director, NINDS. “Gene-targeting strategies like the one shown here now allow us to move from biological discovery straight to therapy development.”
A company that makes an implantable brain-computer interface (BCI) has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.” https://www.engadget.com/fda-brain-computer-interface-clinical-trial-synchron-stentrode-190232289.html?src=rss
A company that makes an implantable has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device’s “safety and efficacy in patients with severe paralysis.”
Synchron received the FDA’s green light ahead of competitors like Elon Musk’s. Before such companies can sell BCIs commercially in the US, they need to prove that the devices work and are safe. The FDA will provide guidance for trials of BCI devices for patients with paralysis or amputation during a webinar on Thursday.
Another clinical trial of Stentrode is underway in Australia. Four patients have received the implant, which is being used “for data transfer from motor cortex to control digital devices,” Synchron said. According to data published in the Journal of NeuroInterventional Surgery, two of the patients were able to control their computer with their thoughts. They completed work-related tasks, sent text messages and emails and did online banking and shopping.
Posted in biotech/medical, computing, Elon Musk, neuroscience | Leave a Comment on This 20-person biotech firm just beat Elon Musk’s Neuralink in getting the OK to test brain chip implants in humans with paralysis
Synchron has beat rival Neuralink to human trials of its “implantable brain computer interface.”
The chip will be studied in six patients later this year as a possible aid for paralyzed people.
Elon Musk previously used Neuralink’s chip in a monkey, which then played video games with its mind.
Synchron beat out rival Neuralink, led by Elon Musk, to get the FDA go-ahead for human trials of a chip implant that makes a brain-computer interface.
Several Clostridium species enriched in children with autism closely interacted with each other and formed a connected group. Clostridia species have been linked with autism via the production of clostridial toxins which can damage the central nervous system, point out the researchers.
Significantly fewer gut bugs linked to neurotransmitter activity.
Children with autism seem to have a distinctive and underdeveloped range and volume of gut bacteria (microbiome) that isn’t related to their diet, suggests a small study published online in the journal Gut.
They have significantly fewer bacteria linked to neurotransmitter activity and 5 species of bacteria that aren’t typically found in the guts of children without the condition, suggesting that there may be a characteristic microbial profile for autism, which may pave the way for treatment early on, say the researchers.
A technique developed at Western University to visually iron out the wrinkles and folds in one region of the brain may provide researchers a more accurate picture to understand brain disorders.
The hippocampus is a region of the brain often looked at by clinicians and researchers for clues to understand disease progression and response to treatment for brain disorders. Made up of two seahorse-shaped brain structures, the hippocampus is located at the centre of the brain and plays an important role in memory formation.
It is one of the first regions of the brain to show damage from Alzheimer’s and other neurodegenerative diseases and is implicated in epilepsy and major depressive disorder. The anatomy of the hippocampus differs greatly from person to person, specifically when looking at the way that it folds in on itself.
Thrilled to see Paradromics’ $20M fund raise lead by the talented Dr. Amy Kruse! Paradromics is building a brain computer interface supported by DARPA’s Biologi… See More.
The investment demonstrates confidence in Paradromics as a well-positioned player in the $200 billion BCI therapy market. Last year, Paradromics successfully completed testing of its platform, demonstrating the largest ever electrical recording of cortical activity that exceeded more than 30000 electrode channels in sheep cortex. This recording allowed researchers to observe the brain activity of sheep in response to sound stimuli with high fidelity.
“We are combining the best of neural science and medical device engineering to create a robust and reliable platform for new clinical therapies,” said Paradromics CEO Matt Angle. “This funding round is a validation of both our technology and strategic vision in leading this important developing market.”
The current funding round follows $10M in early stage private funding as well as $15M of public funding from the National Institutes of Health (NIH) and the Department of Defense (DARPA).
Summary: Study reveals an abundance of the CRMP2 protein in people with schizophrenia. The findings could lead to a blood-based biomarker test for the mental health disorder.
Source: SBPMDI
Scientists at Sanford Burnham Prebys have discovered how levels of a protein could be used in the future as a blood-based diagnostic aid for schizophrenia. The activity of the protein, which is found in both the brain and blood, affects neural connections in human brains and is uniquely imbalanced in people diagnosed with the condition. The research also provides guidance for future analyses into the molecular basis of this serious, disabling mental disorder.
After controlling for factors such as age, sex, handedness, first language, education level, and other variables, the researchers found that those who had contracted COVID-19 tended to underperform on the intelligence test compared to those who had not contracted the virus. The greatest deficits were observed on tasks requiring reasoning, planning and problem solving, which is in line “with reports of long-COVID, where ‘brain fog,’ trouble concentrating and difficulty finding the correct words are common,” the researchers said.
People who have recovered from COVID-19 tend to score significantly lower on an intelligence test compared to those who have not contracted the virus, according to new research published in The Lancet journal EClinicalMedicine. The findings suggest that the SARS-CoV-2 virus that causes COVID-19 can produce substantial reductions in cognitive ability, especially among those with more severe illness.
“By coincidence, the pandemic escalated in the United Kingdom in the middle of when I was collecting cognitive and mental health data at very large scale as part of the BBC2 Horizon collaboration the Great British Intelligence Test,” said lead researcher Adam Hampshire (@HampshireHub), an associate professor in the Computational, Cognitive and Clinical Neuroimaging Laboratory at Imperial College London.
“The test comprised a set of tasks designed to measure different dimensions of cognitive ability that had been designed for application in both citizen science and clinical research. A number of my colleagues contacted me in parallel to point out that this provided an opportunity to gather important data on how the pandemic and COVID-19 illness were affecting mental health and cognition.”
“It’s an extraordinary paper with some extraordinary claims,” says Gray Camp, a developmental biologist at the University of Basel in Switzerland, whose lab last year reported2 growing brain organoids that contained a gene common to Neanderthals and humans. The latest work takes the research further by looking at gene variants that humans lost in evolution. But Camp remains sceptical about the implications of the results, and says the work opens more questions that will require investigation.
Humans are more closely related to Neanderthals and Denisovans than to any living primate, and some 40% of the Neanderthal genome can still be found spread throughout living humans. But researchers have limited means to study these ancient species’ brains — soft tissue is not well preserved, and most studies rely on inspecting the size and shape of fossilized skulls. Knowing how the species’ genes differ from humans’ is important because it helps researchers to understand what makes humans unique — especially in our brains.
The researchers, led by Alysson Muotri, a neuroscientist at the University of California, San Diego, used the genome-editing technique CRISPR–Cas9 to introduce the Neanderthal and Denisovan form of a gene called NOVA1 into human pluripotent stem cells, which can develop into any cell type. They cultured these to form organoids, clumps of brain-like tissue, up to 5 millimetres across, alongside normal human brain organoids for comparison.
